First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis

BACKGROUND: Anti-PD-1 antibodies and BRAF/MEK inhibitors are the two main groups of systemic therapy in the treatment of BRAF(V600)-mutant advanced melanoma. Until now, data are inconclusive on which therapy to use as first-line treatment. The aim of this study was to use propensity score matching t...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Cancer
Asıl Yazarlar: van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., Tije, Bert-Jan J. ten, Veldt, Astrid A. M. van der, Vreugdenhil, Art, Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J. M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2021
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8007796/
https://ncbi.nlm.nih.gov/pubmed/33495600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-01229-1
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller